Enrico Pesenti

Predictive Pharmacokinetic-Pharmacodynamic Modeling of Tumor Growth Kinetics in Xenograft Models after Administration of Anticancer Agents

Monica Simeoni, Paolo Magni, Cristiano Cammia et al. · Cancer Research · 2004 · 499 citations · Full text

Medicine, Oncology, Pharmacology +16

Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications

Elena Ardini, Maria Menichincheri, Patrizia Banfi et al. · Molecular Cancer Therapeutics · 2016 · 312 citations · Full text

Medicine, Oncology, Pharmacology +17

Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor

Maria Menichincheri, Elena Ardini, Paola Magnaghi et al. · Journal of Medicinal Chemistry · 2016 · 298 citations · Full text

Medicine, Oncology, Pharmacology +17

Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer.

Tinya J. Abrams, Lesley Murray, Enrico Pesenti et al. · PubMed · 2003 · 252 citations

Medicine, Oncology, Pharmacology +17

PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer

Patrizia Carpinelli, Roberta Ceruti, Maria Laura Giorgini et al. · Molecular Cancer Therapeutics · 2007 · 244 citations

Medicine, Oncology, Pharmacology +16